Home | Back to newsletter main page
 |
|
December 6, 2010 |
|
MESSAGE FROM THE DIRECTORThis Year at the ASH Annual MeetingMembers of the Case Comprehensive Cancer Center have made major contributions to the field of hematology and oncology, and were recognized at this year's ASH Annual Meeting in Orlando. Last week, we provided a list of the abstract titles and today, some of the presentations have yet to be given. I would like to recognize the many labs and clinical groups who made presentations in hematology, hematological malignancies, and stem cell transplantation. Of note, for the first time in at least 30 years, and I suspect, ever, TWO of the six abstracts presented in the ASH plenary session were from Cancer Center members. Anna Jankowska from the lab led by Jaroslaw Maciejewski, MD, PhD gave a wonderful talk to over 10,000 members of ASH on Impaired Hydroxylation of 5-Methylcytosine In TET2 mutated Patients with Myeloid Malignancies. They were the first to show the frequency of TET2 mutations in hematological malignancies – AML and MDS – and to show how loss of TET2 alters the genomic methylation patterns by decreasing the conversion of Methylcytosine to Hydroxymethylcytosine, giving rise to altered gene expression that provides epigenetic changes that appear essential for the function of these hematologic malignancies. The second plenary abstract was from the lab of Ed Plow, PhD and was presented by Elzbieta Pluskota, PhD, titled The Integrin Co-Activator Kindlin-2 Plays a Critical Role In Angiogenesis and Blood Vessel Integrity. Ed has studied the integrin binding protein Kindlin-2, and has discovered its role in vasculogenesis with very clear data on the function it has in endothelial cells in mediating proper vascular development. Kindlin-2 mutation results in loss of function, loss of endothelial cell migration, and a clear impact in nonvascular development. This opens the door for further studies in congenital diseases and the targeting of this molecule as an antiangiogenesis strategy. Many other outstanding presentations are ongoing through Tuesday. Drs. Eric Hsi, Mikkael A. Sekeres, Jaroslaw Maciejewski, and Hillard Lazarus deserve to be singled out for their multiple abstracts representing our institutions. Stan Gerson, MD CASE CCC IN THE NEWSJust Breathe: Body Has A Built-In Stress Reliever Glaxo Fails to Win Panel's Backing to Expand Avodart for Cancer R. Livingston Ireland's effort helped create UH's Cancer Center Jane and Lee Seidman Donate $42 Million to University Hospitals for Cancer Center NEW MEMBERS CORNERPlease join us in welcoming the newest members of the Case CCC: Fadi Abdul-Karim, MD Kenneth Cummings, MD Jung-won Lim, PhD Nicole Steinmetz, PhD ANNOUNCEMENTSApplied Biostatistics in Clinical Research CourseThe CTSC is pleased to offer a free 9-week seminar series on applied biostatistics in clinical research. Dr. Mark Schluchter, Professor of Epidemiology & Biostatistics and Director of the Biostatistics Core Facility, will teach the course Wednesdays from 4-5:30 pm, starting January 12, 2011. Click here to register for the course of for additional information. FUNDING OPPORTUNITIESAACI Translational Cancer Research FellowshipApplications are now open for the inaugural AACI Translational Cancer Research Fellowship. This $50,000 one-year non-renewable grant will support post-doctoral training to individuals who have completed at least one year of training in any field of oncology and have at least one year of training remaining at an AACI member institution. Only ONE application per institution. Anyone interested in applying should send an abstract to tld6@case.edu by Wednesday, December 8. External Deadline: December 17 Interinstitutional Basic, Clinical and Translational Research Projects in CancerThe Case CCC will provide seed money to foster collaborations and promote and increase institution-wide capacity and competitiveness in basic, clinical or translational research that is aligned with the Cancer Center Scientific Programs and spans the institutions of the Case CCC. 2-3 awards of $75,000 - $100,000 will be made. Faculty at all levels with interests in cancer research are encouraged to apply. Proposals require a minimum of two PIs: one from Case/UH and one from Cleveland Clinic. Proposals must involve new collaborative work with no joint publications or grants related to the current project. Applications will be submitted through http://webgrants.case.edu. Deadline: January 18, 2011 Complete information is available on the Cancer Center website. James S. McDonnell Foundation: 21st Century Science InitiativeThe James S. McDonnell Foundation announces updated program descriptions and application guidelines for its 21st Century Science Initiative Research Awards. These awards support investigator-initiated research in two topical areas: Studying Complex Systems and Brain Cancer Research. Deadline: March 15, 2011 AICR Research Grant ProgramThe AICR Research Grant Program encourages innovative research on food, nutrition, physical activity and weight management in relation to cancer prevention, treatment, and survivorship. AICR offers three types of research grants: Investigator Initiated Grants (IIGs), Matching Grants, and Postdoctoral Awards (PDAs). All applications must bear the signature of the official head of the organization or that of a designee, since grants are not made to individual researchers, but to the relevant institution. External LOI Deadline: January 25, 2011 AACR Colorectal Cancer Coalition-AACR Fellowship, in memory of Lisa DubowThe Colorectal Cancer Coalition-AACR Fellowship, in memory of Lisa Dubow is a one‐year grant of $45,000 to support the salary and benefits of the fellow. Research projects are restricted to translational or clinical cancer research that has an ultimate goal of developing or improving therapeutic interventions for patients with metastatic colorectal cancer. It is anticipated one Fellowship will be funded. *Extended* Application Deadline: December 8 |
EVENTS
**All events are open to anyone interested in attending December 6Pathology Research Seminar December 7December 8Hematology and Oncology Division Research Conference Department of Genetics, Office of Graduate Education, Minority Graduate Education Student Organization, and PREP Program Seminar Immunology Invited Speaker Seminar Series Pathology Graduate Student Seminar NCRM Seminar December 9Biochemistry Seminar Neurosciences Seminar Biochemistry Seminar Cell Death Regulation Program Meeting December 10Hematology and Oncology Fellows Conference Cell Biology Seminar Series Cancer Center Research in Progress Seminar
UPCOMING CANCER CENTER SYMPOSIUMS & EVENTSCancer Center Seminar Series ADDITIONAL UPCOMING SEMINARS & EVENTSActive Living Research Annual Conference Multilevel Interventions in Health Care: Building the Foundation for Future Research Goals 4th Annual Biospecimen Research Network (BRN) Symposium: Advancing Cancer Research Through Biospecimen Science Call for Abstracts: 2011 Clinical and Translational Research and Education Meeting: ACRT/SCTS Joint Annual Meeting Cancer Health Disparities Summit 2011 |
MARK YOUR CALENDARSCancer Imaging Nanotechnology Sub-group MeetingDrs. Jim Basilion and Zhenghong Lee would like to extend an invitation to the Case Comprehensive Cancer Imaging Program members to attend the next meeting of the Cancer Imaging Nanotechnology Sub-Group. The meeting will take place January 10 from 4-5 pm in the CCIR Conference Room, Wearn B-37. Please contact Marianne Sperk with any questions. Second Oncomine WorkshopThe Second Oncomine workshop will occur on Tuesday, December 14 from 2-3 pm in SOM E324. To derive any benefit from the workshop, you must be registered with www.oncomine.org. We will revisit the basics covered in the first workshop, and extend ourselves a little further. Don't miss this opportunity to learn how to make your next grant proposal look better. Places are limited contact Patrick.Leahy@case.edu to reserve your spot. Clinical Assay Development Program WorkshopRegistration is open for a December 14 workshop on the NCI's new Clinical Assay Development Program (CADP), which aims to bridge the gap between promising research-based assays under development and validated, clinically useful cancer diagnostic tests. The CADP will assess and advise on how to develop an assay further and offer services to optimize analytical performance and establish clinical validity. This effort will allow the clinical utility of the assay and its diagnostic significance to be evaluated in well-designed clinical studies. This is not a grant program but provides access to services for clinical assay development. Applications for CADP resources will be accepted early in 2011. Workshop participants will have an opportunity to learn more about the Clinical Assay Development Program, and to provide input on improving this resource. A description of what the CADP offers, who is eligible to apply, and how the program will function will be discussed. Click here to register. Registration open through December 6. Space at the workshop is limited to 200 attendees. |
NCI CANCER BULLETINSpecial Issue: Global CollaborationCommentary News Highlights Updates |
PREVIOUSLY ANNOUNCED FUNDING OPPORTUNITIES |
|
|
Susan G. Komen for the Cure Promise Grants |
AICR Postdoctoral Awards (PDAs) |
NIH BULLETIN – Notices and Funding OpportunitiesDevelopmental Pharmacology (R01) (PAR-11-057) |
|
| Produced by: Gillian Irwin Todd 11100 Euclid Avenue, Wearn 149 Cleveland, Ohio 44106-5065 216-844-8317 phone 216-844-7832 fax gillian.irwin@case.edu |
HELP US HELP YOU!If you have a new grant, recently won an award, or have other newsworthy items, please let us know so we can publicize them in the newsletter and other media outlets. You deserve the accolades! Send items to gillian.irwin@case.edu. |
|
|